Sat, Dec 21, 2024
[Archive]
Volume 9, Issue 4 (Nov 2024)
JNFS 2024, 9(4): 672-680 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Wasman Smail S, Khaled Qadir M, Ahmed Hamad Amin O, Rasul D, Elia Ishaq S, Omar khudhur Z, et al . The Efficacy and Safety of Green-Lipped Mussel Extract Plus Ginkgo Biloba on Anti-Inflammatory Status in Patients with Knee Osteoarthritis. JNFS 2024; 9 (4) :672-680
URL: http://jnfs.ssu.ac.ir/article-1-783-en.html
URL: http://jnfs.ssu.ac.ir/article-1-783-en.html
Shukur Wasman Smail 
, Mahdi Khaled Qadir , Omer Ahmed Hamad Amin , Dedawan Rasul , Sonia Elia Ishaq , Zhikal Omar khudhur , Mohammed Ibrahim Mohialdeen Gubari , Kurosh Djafarian *
, Mahdi Khaled Qadir , Omer Ahmed Hamad Amin , Dedawan Rasul , Sonia Elia Ishaq , Zhikal Omar khudhur , Mohammed Ibrahim Mohialdeen Gubari , Kurosh Djafarian *
Department of Clinical Nutrition, School of Nutrition and Dietetics, Tehran University of Medical Science, Tehran, Iran
Abstract: (735 Views)
Clinical research on the efficacy of nutraceutical compounds recommended for the relief of osteoarthritis (OA) symptoms has been largely disputed. In addition, no link has been established between its safety and efficacy in Kurdish population. The aim of this study is to determine the efficacy of New Zealand green-lipped mussel extract + Ginkgo biloba (GLME+) in patients with OA, and analyze the effect of GLME+ on inflammation. Methods: In an open-label, single-group allocation study, 40 patients diagnosed with knee OA were administrated 1000 mg/day of New Zealand green-lipped mussel extract and 100 mg/day of Ginkgo biloba for eight weeks. The outcome measure was scored using Western Ontario and McMaster Universities arthritis index (WOMAC). The serum concentration of inflammatory chemokine (CCL3) and myeloperoxidase (MPO) were measured. An intention-to-treat analysis was employed and subject data at T0 and T8 weeks. Results: Results showed a significant improvement in WOMAC score in post-treated OA patients with GLME+ (P<0.001). In addition, CCL3 serum levels were significantly decreased after an 8-week intervention (P<0.001). Moreover, no statistical significance was observed within groups in MPO serum levels (P> 0.05). Conclusions: GLME+ improved knee joint pain, stiffness, and mobility in OA patients. Two of GLME+'s chondroprotective properties were the reduction of oxidative damage and the inhibition of inflammation, both of which have been linked to the etiology of OA cartilage destruction. The findings indicated that GLME+ may be useful in the treatment of OA patients.
Type of article: orginal article |
Subject:
public specific
Received: 2022/12/10 | Published: 2024/11/20 | ePublished: 2024/11/20
Received: 2022/12/10 | Published: 2024/11/20 | ePublished: 2024/11/20
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
